ImmuCell (ICCC) to Post Earnings on Thursday

ImmuCell (NASDAQ:ICCC) is projected to announce its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to post earnings of $0.05 per share and revenue of $5.4010 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:00 AM ET.

ImmuCell (NASDAQ:ICCC) last posted its quarterly earnings data on Thursday, May 14th. The biotechnology company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.16. The business had revenue of $10.36 million for the quarter, compared to analyst estimates of $5.40 million. ImmuCell had a negative return on equity of 1.88% and a negative net margin of 1.82%.

ImmuCell Stock Performance

Shares of NASDAQ ICCC opened at $10.95 on Wednesday. ImmuCell has a 12 month low of $4.52 and a 12 month high of $12.10. The company has a market cap of $99.10 million, a P/E ratio of -182.47 and a beta of 0.54. The business’s 50 day moving average is $10.46 and its two-hundred day moving average is $8.44. The company has a quick ratio of 2.60, a current ratio of 4.82 and a debt-to-equity ratio of 0.24.

Insider Buying and Selling

In other news, CEO Boekhorst Paul Francis Oliv Te acquired 8,000 shares of ImmuCell stock in a transaction on Thursday, June 18th. The stock was bought at an average price of $9.49 per share, for a total transaction of $75,920.00. Following the transaction, the chief executive officer owned 17,785 shares of the company’s stock, valued at $168,779.65. The trade was a 81.76% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 5.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in ImmuCell stock. Geode Capital Management LLC raised its holdings in ImmuCell Corporation (NASDAQ:ICCC) by 4.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 71,852 shares of the biotechnology company’s stock after buying an additional 2,907 shares during the quarter. Geode Capital Management LLC owned 0.79% of ImmuCell worth $500,000 as of its most recent SEC filing. 13.47% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ICCC shares. Weiss Ratings restated a “sell (d-)” rating on shares of ImmuCell in a research note on Thursday, July 2nd. Wall Street Zen raised shares of ImmuCell to a “strong-buy” rating in a report on Saturday, June 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.